FI61893C - Foerfarande foer framstaellning av antiinflammatoriska fenylbutazon-enolesterderivat - Google Patents
Foerfarande foer framstaellning av antiinflammatoriska fenylbutazon-enolesterderivat Download PDFInfo
- Publication number
- FI61893C FI61893C FI752387A FI752387A FI61893C FI 61893 C FI61893 C FI 61893C FI 752387 A FI752387 A FI 752387A FI 752387 A FI752387 A FI 752387A FI 61893 C FI61893 C FI 61893C
- Authority
- FI
- Finland
- Prior art keywords
- phenylbutazone
- proline
- enolesterderivat
- antiinflammatoriska
- fenylbutazon
- Prior art date
Links
- 229960002895 phenylbutazone Drugs 0.000 claims description 24
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 21
- 229960002429 proline Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- -1 phenylbutazone enol ester Chemical class 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 8
- 229930182821 L-proline Natural products 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GNMSLDIYJOSUSW-LURJTMIESA-N N-acetyl-L-proline Chemical compound CC(=O)N1CCC[C@H]1C(O)=O GNMSLDIYJOSUSW-LURJTMIESA-N 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GNMSLDIYJOSUSW-UHFFFAOYSA-N N-Acetyl-proline Chemical compound CC(=O)N1CCCC1C(O)=O GNMSLDIYJOSUSW-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- VPODXHOUBDCEHN-UHFFFAOYSA-N pyridine-3-carbonyl pyridine-3-carboxylate Chemical compound C=1C=CN=CC=1C(=O)OC(=O)C1=CC=CN=C1 VPODXHOUBDCEHN-UHFFFAOYSA-N 0.000 description 1
- ORBIGZZHMAJXAZ-UHFFFAOYSA-N pyridine-4-carbonyl pyridine-4-carboxylate Chemical compound C=1C=NC=CC=1C(=O)OC(=O)C1=CC=NC=C1 ORBIGZZHMAJXAZ-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7429109 | 1974-08-26 | ||
| FR7429109A FR2282884A1 (fr) | 1974-08-26 | 1974-08-26 | Nouveaux derives de la phenylbutazone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI752387A7 FI752387A7 (en:Method) | 1976-02-27 |
| FI61893B FI61893B (fi) | 1982-06-30 |
| FI61893C true FI61893C (fi) | 1982-10-11 |
Family
ID=9142574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI752387A FI61893C (fi) | 1974-08-26 | 1975-08-25 | Foerfarande foer framstaellning av antiinflammatoriska fenylbutazon-enolesterderivat |
Country Status (13)
| Country | Link |
|---|---|
| AT (1) | AT343111B (en:Method) |
| BE (1) | BE832722A (en:Method) |
| CH (1) | CH615434A5 (en:Method) |
| DE (1) | DE2537590A1 (en:Method) |
| DK (1) | DK138495B (en:Method) |
| FI (1) | FI61893C (en:Method) |
| FR (1) | FR2282884A1 (en:Method) |
| GB (1) | GB1482380A (en:Method) |
| IE (1) | IE41788B1 (en:Method) |
| LU (1) | LU73250A1 (en:Method) |
| NL (1) | NL7509999A (en:Method) |
| NO (1) | NO142220C (en:Method) |
| SE (1) | SE421618B (en:Method) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1604045A (en) * | 1977-06-01 | 1981-12-02 | Sterwin Ag | -(2-methyl-indol-3-yl)-acetic acid esters processes for its prepartion and pharmaceutical compositions incorporating the same |
-
1974
- 1974-08-26 FR FR7429109A patent/FR2282884A1/fr active Granted
-
1975
- 1975-08-22 AT AT650175A patent/AT343111B/de not_active IP Right Cessation
- 1975-08-23 DE DE19752537590 patent/DE2537590A1/de not_active Ceased
- 1975-08-25 SE SE7509449A patent/SE421618B/xx unknown
- 1975-08-25 NL NL7509999A patent/NL7509999A/xx unknown
- 1975-08-25 BE BE159444A patent/BE832722A/xx not_active IP Right Cessation
- 1975-08-25 NO NO752923A patent/NO142220C/no unknown
- 1975-08-25 IE IE1861/75A patent/IE41788B1/en unknown
- 1975-08-25 DK DK381075AA patent/DK138495B/da unknown
- 1975-08-25 LU LU73250A patent/LU73250A1/xx unknown
- 1975-08-25 FI FI752387A patent/FI61893C/fi not_active IP Right Cessation
- 1975-08-26 CH CH1107275A patent/CH615434A5/de not_active IP Right Cessation
- 1975-08-26 GB GB35252/75A patent/GB1482380A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL7509999A (nl) | 1976-03-01 |
| ATA650175A (de) | 1977-09-15 |
| FR2282884B1 (en:Method) | 1978-07-21 |
| DK138495C (en:Method) | 1979-03-05 |
| NO142220B (no) | 1980-04-08 |
| IE41788L (en) | 1976-02-26 |
| LU73250A1 (en:Method) | 1977-01-07 |
| FI61893B (fi) | 1982-06-30 |
| IE41788B1 (en) | 1980-03-26 |
| SE7509449L (sv) | 1976-02-27 |
| NO752923L (en:Method) | 1976-02-27 |
| AT343111B (de) | 1978-05-10 |
| FR2282884A1 (fr) | 1976-03-26 |
| DK138495B (da) | 1978-09-18 |
| BE832722A (fr) | 1976-02-25 |
| SE421618B (sv) | 1982-01-18 |
| DE2537590A1 (de) | 1976-03-11 |
| DK381075A (en:Method) | 1976-02-27 |
| FI752387A7 (en:Method) | 1976-02-27 |
| NO142220C (no) | 1980-07-16 |
| CH615434A5 (en) | 1980-01-31 |
| GB1482380A (en) | 1977-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5137918A (en) | N-(2'-aminophenyl)-benzamide derivatives process for the preparation thereof and pharmaceutical compositions containing them | |
| CN101500983A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药 | |
| US3988446A (en) | Glycerides with anti-inflammatory properties | |
| JP4172045B2 (ja) | イノシトール三燐酸エステルを使用した炎症性障害治療用薬剤 | |
| RU2145598C1 (ru) | Производные колхицина, способ их получения, фармацевтическая композиция | |
| JPS6229566A (ja) | 新規グアニジノメチル安息香酸誘導体 | |
| HUP0100853A2 (hu) | Fekély kezelésére alkalmas nitrátsók és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
| FI61893C (fi) | Foerfarande foer framstaellning av antiinflammatoriska fenylbutazon-enolesterderivat | |
| US3812109A (en) | Substituted indenyl glucoronide esters | |
| US3773936A (en) | Method of treating inflammation with substituted anilino salicylic acids | |
| US4046887A (en) | Glycerides with anti-inflammatory properties | |
| HU194877B (en) | Process for producing morpholinoethyl-ester-diniflumate of nifluminic acid and pharmaceutical composition containing them | |
| KR970011456B1 (ko) | d-2-(6-메톡시-2-나프틸)-프로피온산의 광학활성 유도체와 이것을 함유한 약제학적 조성물 | |
| US4055580A (en) | Derivatives of aminomethylcyclohexanecarboxylic acid | |
| US3833605A (en) | Substituted 1-carboxamidine-pyrazoles and their acid addition salts | |
| JPS5835186A (ja) | ジカルボキシアミノチアゾール誘導体およびそれを含有する免疫調節組成物 | |
| KR860001862B1 (ko) | 디알카노일옥시벤질리덴 디알카노에이트의 제조방법 | |
| US4014997A (en) | Acylphosphonate esters | |
| US3821415A (en) | Heterocyclic compounds in pharmaceutical compositions and methods | |
| JPS609752B2 (ja) | 新規な２−アセトキシベンズアミド誘導体、その製法及びそれを有効成分とする医薬 | |
| JPS609023B2 (ja) | インジルビン誘導体およびそれを含有する抗腫瘍剤 | |
| SU869267A1 (ru) | N-[4-(3,3-Диметилтриазено)-фенилсульфонил]-изовалериламид, про вл ющий противовоспалительное действие | |
| US3181993A (en) | Water-soluble salicylic acid derivatives as analgesics and antipyretics | |
| JPS6011693B2 (ja) | アセチルサリチル酸誘導体、その製造法ならびにそれを含有してなる解熱鎮痛剤および炎症抑制剤 | |
| US3225053A (en) | Quebrachidine and derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: SOCIETE PLURIPHARM |